ProCE Banner Activity

Strategies for Optimal HIV Treatment and Prevention: Considering Cabotegravir in Pregnancy

Slideset Download
See available data and recommendations for the use of long-acting cabotegravir in pregnancy, as well as key considerations for deciding whether to switch ART for someone who becomes pregnant while virologically suppressed on long-acting cabotegravir and rilpivirine.

Released: October 21, 2022

Expiration: October 20, 2023

No longer available for credit.
Begin Activity

Share

Faculty

William R. Short

William R. Short, MD, MPH, FIDSA

Associate Director of the HIV Clinical Trials Unit
Associate Professor of Medicine and Obstetrics and Gynecology
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

William R. Short, MD, MPH, FIDSA

Associate Director of the HIV Clinical Trials Unit
Associate Professor of Medicine and Obstetrics and Gynecology
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania